C4 Therapeutics (CCCC) Equity Average (2019 - 2026)

C4 Therapeutics has reported Equity Average for 8 years, with the latest figure at $245.4 million in Q1 2026.

• For the quarter ending Q1 2026, Equity Average rose 19.39% year-over-year to $245.4 million; the trailing twelve-month figure through Mar 2026 stood at $245.4 million (up 19.39% YoY), and the FY2025 full-year result was $236.3 million, up 2.27% from the prior year.
• Equity Average for Q1 2026 stood at $245.4 million, up from $205.5 million in the prior quarter.
• The five-year high for Equity Average was $377.1 million in Q1 2022, with the low at $164.2 million in Q3 2025.
• Average Equity Average over 5 years is $254.8 million, with a median of $245.4 million recorded in 2026.
• Year-over-year, Equity Average soared 38.5% in 2022 and tumbled 32.93% in 2025.
• Tracing CCCC's Equity Average over 5 years: stood at $303.7 million in 2022, then fell by 23.92% to $231.1 million in 2023, then dropped by 0.76% to $229.3 million in 2024, then slipped by 10.39% to $205.5 million in 2025, then gained by 19.43% to $245.4 million in 2026.
• The last three Equity Average figures came in at $245.4 million (Q1 2026), $205.5 million (Q4 2025), and $164.2 million (Q3 2025), per Business Quant data.

Peer Comparison